Defining EGFR amplification status for clinical trial inclusionPim J. French, Martin J. van den Bent, Johan M. Kros et al.|Neuro-Oncology|2019Cited by 44
EGFR mutations are associated with response to depatux-m in combination with temozolomide and result in a receptor that is hypersensitive to ligandYouri Hoogstrate, Pim J. French, Wies Vallentgoed et al.|Neuro-Oncology Advances|2019Cited by 17